Statin Therapy in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention (from the Evaluation of Drug Eluting Stents and Ischemic Events Registry)
Secondary prevention trials have demonstrated the efficacy of statins in reducing cardiovascular morbidity and mortality in patients with coronary artery disease and events after percutaneous coronary intervention (PCI). However, there are few data describing the clinical value of statins in patient...
Gespeichert in:
| Veröffentlicht in: | The American journal of cardiology 2014-02, Vol.113 (4), p.621-625 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 625 |
|---|---|
| container_issue | 4 |
| container_start_page | 621 |
| container_title | The American journal of cardiology |
| container_volume | 113 |
| creator | Dasari, Tarun W., MD, MPH Cohen, David J., MD, MSc Kleiman, Neal S., MD Keyes, Michelle J., PhD Yen, Chen-Hsing, MS Hanna, Elias B., MD Saucedo, Jorge F., MD |
| description | Secondary prevention trials have demonstrated the efficacy of statins in reducing cardiovascular morbidity and mortality in patients with coronary artery disease and events after percutaneous coronary intervention (PCI). However, there are few data describing the clinical value of statins in patients with coronary artery disease and chronic kidney disease (CKD) undergoing PCI. Of 10,148 patients who entered into Evaluation of Drug Eluting Stents and Ischemic Events, a multicenter registry of unselected patients undergoing PCI from July 2004 to December 2007, we studied 2,306 patients with CKD (estimated glomerular filtration rate ≤60 ml/min based on the Modified Diet in Renal Disease calculation). Patients were stratified into those receiving statins at discharge (n = 1,833, 79%) or not (n = 473, 21%). Patients in the statin group had a greater prevalence of hypertension, recent myocardial infarction (MI), and use of β blockers and angiotensin-converting enzyme inhibitors. Outcomes were assessed from discharge through 1-year follow-up. One-year all-cause mortality was 5.7% in statin group versus 8.7% in the no statin group (adjusted hazard ratio 0.55, 95% confidence interval 0.34 to 0.88). The composite of death, MI, and repeat revascularization was lower in statin group (adjusted hazard ratio 0.71, 95% confidence interval 0.51 to 0.99). In conclusion, among patients with CKD undergoing PCI, the prescription of statins at hospital discharge was associated with a significant improvement in subsequent outcomes including mortality and composite end point of death, MI, and repeat revascularization. |
| doi_str_mv | 10.1016/j.amjcard.2013.11.006 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1494306406</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0002914913022509</els_id><sourcerecordid>3195386471</sourcerecordid><originalsourceid>FETCH-LOGICAL-c448t-c4a15a3364266d4c818417d4c376951904d8ba8031c46f049d8134d818c790643</originalsourceid><addsrcrecordid>eNqFUsGO0zAUtBCILYVPAFnishxa_GLHSS4g1C1QsRIruiuOltd5bV2SuNhOpf4U34jTFpD2wsV-Ho1n_N6YkJfApsBAvt1Odbs12tfTjAGfAkwZk4_ICMqimkAF_DEZMcaySQWiuiDPQtimI0Aun5KLTHCRFTIbkV_LqKPt6O0Gvd4daCpvEoBdDPS7jRs623jXWUO_2LrDA72yAXVAetfV6NfOdmt6g970UXfo-kBnLtG1P9BFF9Hvk451Hb1cedfSuEE63-um10fQreiV79d03vRx0FnGo6vuaroIZoNtcp3vj9g3XNsQ_eHNc_JkpZuAL877mNx9nN_OPk-uv35azD5cT4wQZUyrhlxzLkUmZS1MCaWAIhW8kFUOFRN1ea9LxsEIuWKiqkvgCYPSFBWTgo_J5Ul3593PHkNUrQ0Gm-bUpkozFTwRmUzU1w-oW9f7Lr1uYGV5kefJaEzyE8t4F4LHldp526ZBKWBqCFRt1TlQNQSqABQ7qr86q_f3LdZ_b_1JMBHenwiYxrG36FUwKT6DtfVooqqd_a_FuwcKprEpct38wAOGf92okCmmlsOvGj4VcJZlOav4b0DYyX0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1492575580</pqid></control><display><type>article</type><title>Statin Therapy in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention (from the Evaluation of Drug Eluting Stents and Ischemic Events Registry)</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>ProQuest Central UK/Ireland</source><creator>Dasari, Tarun W., MD, MPH ; Cohen, David J., MD, MSc ; Kleiman, Neal S., MD ; Keyes, Michelle J., PhD ; Yen, Chen-Hsing, MS ; Hanna, Elias B., MD ; Saucedo, Jorge F., MD</creator><creatorcontrib>Dasari, Tarun W., MD, MPH ; Cohen, David J., MD, MSc ; Kleiman, Neal S., MD ; Keyes, Michelle J., PhD ; Yen, Chen-Hsing, MS ; Hanna, Elias B., MD ; Saucedo, Jorge F., MD</creatorcontrib><description>Secondary prevention trials have demonstrated the efficacy of statins in reducing cardiovascular morbidity and mortality in patients with coronary artery disease and events after percutaneous coronary intervention (PCI). However, there are few data describing the clinical value of statins in patients with coronary artery disease and chronic kidney disease (CKD) undergoing PCI. Of 10,148 patients who entered into Evaluation of Drug Eluting Stents and Ischemic Events, a multicenter registry of unselected patients undergoing PCI from July 2004 to December 2007, we studied 2,306 patients with CKD (estimated glomerular filtration rate ≤60 ml/min based on the Modified Diet in Renal Disease calculation). Patients were stratified into those receiving statins at discharge (n = 1,833, 79%) or not (n = 473, 21%). Patients in the statin group had a greater prevalence of hypertension, recent myocardial infarction (MI), and use of β blockers and angiotensin-converting enzyme inhibitors. Outcomes were assessed from discharge through 1-year follow-up. One-year all-cause mortality was 5.7% in statin group versus 8.7% in the no statin group (adjusted hazard ratio 0.55, 95% confidence interval 0.34 to 0.88). The composite of death, MI, and repeat revascularization was lower in statin group (adjusted hazard ratio 0.71, 95% confidence interval 0.51 to 0.99). In conclusion, among patients with CKD undergoing PCI, the prescription of statins at hospital discharge was associated with a significant improvement in subsequent outcomes including mortality and composite end point of death, MI, and repeat revascularization.</description><identifier>ISSN: 0002-9149</identifier><identifier>EISSN: 1879-1913</identifier><identifier>DOI: 10.1016/j.amjcard.2013.11.006</identifier><identifier>PMID: 24342762</identifier><identifier>CODEN: AJCDAG</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Aged, 80 and over ; Cardiovascular ; Coronary Artery Disease - complications ; Coronary Artery Disease - mortality ; Coronary Artery Disease - surgery ; Drug Prescriptions - statistics & numerical data ; Drug therapy ; Drug-Eluting Stents ; Female ; Follow-Up Studies ; Glomerular Filtration Rate ; Heart attacks ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Male ; Mortality ; Percutaneous Coronary Intervention ; Platelet Aggregation Inhibitors - therapeutic use ; Prospective Studies ; Registries ; Renal Insufficiency, Chronic - complications ; Renal Insufficiency, Chronic - drug therapy ; Renal Insufficiency, Chronic - mortality ; Statins ; Survival Rate ; Treatment Outcome</subject><ispartof>The American journal of cardiology, 2014-02, Vol.113 (4), p.621-625</ispartof><rights>Elsevier Inc.</rights><rights>2014 Elsevier Inc.</rights><rights>Copyright © 2014 Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited Feb 15, 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c448t-c4a15a3364266d4c818417d4c376951904d8ba8031c46f049d8134d818c790643</citedby><cites>FETCH-LOGICAL-c448t-c4a15a3364266d4c818417d4c376951904d8ba8031c46f049d8134d818c790643</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1492575580?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,64361,64363,64365,65309,72215</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24342762$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dasari, Tarun W., MD, MPH</creatorcontrib><creatorcontrib>Cohen, David J., MD, MSc</creatorcontrib><creatorcontrib>Kleiman, Neal S., MD</creatorcontrib><creatorcontrib>Keyes, Michelle J., PhD</creatorcontrib><creatorcontrib>Yen, Chen-Hsing, MS</creatorcontrib><creatorcontrib>Hanna, Elias B., MD</creatorcontrib><creatorcontrib>Saucedo, Jorge F., MD</creatorcontrib><title>Statin Therapy in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention (from the Evaluation of Drug Eluting Stents and Ischemic Events Registry)</title><title>The American journal of cardiology</title><addtitle>Am J Cardiol</addtitle><description>Secondary prevention trials have demonstrated the efficacy of statins in reducing cardiovascular morbidity and mortality in patients with coronary artery disease and events after percutaneous coronary intervention (PCI). However, there are few data describing the clinical value of statins in patients with coronary artery disease and chronic kidney disease (CKD) undergoing PCI. Of 10,148 patients who entered into Evaluation of Drug Eluting Stents and Ischemic Events, a multicenter registry of unselected patients undergoing PCI from July 2004 to December 2007, we studied 2,306 patients with CKD (estimated glomerular filtration rate ≤60 ml/min based on the Modified Diet in Renal Disease calculation). Patients were stratified into those receiving statins at discharge (n = 1,833, 79%) or not (n = 473, 21%). Patients in the statin group had a greater prevalence of hypertension, recent myocardial infarction (MI), and use of β blockers and angiotensin-converting enzyme inhibitors. Outcomes were assessed from discharge through 1-year follow-up. One-year all-cause mortality was 5.7% in statin group versus 8.7% in the no statin group (adjusted hazard ratio 0.55, 95% confidence interval 0.34 to 0.88). The composite of death, MI, and repeat revascularization was lower in statin group (adjusted hazard ratio 0.71, 95% confidence interval 0.51 to 0.99). In conclusion, among patients with CKD undergoing PCI, the prescription of statins at hospital discharge was associated with a significant improvement in subsequent outcomes including mortality and composite end point of death, MI, and repeat revascularization.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Cardiovascular</subject><subject>Coronary Artery Disease - complications</subject><subject>Coronary Artery Disease - mortality</subject><subject>Coronary Artery Disease - surgery</subject><subject>Drug Prescriptions - statistics & numerical data</subject><subject>Drug therapy</subject><subject>Drug-Eluting Stents</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Glomerular Filtration Rate</subject><subject>Heart attacks</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Male</subject><subject>Mortality</subject><subject>Percutaneous Coronary Intervention</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Prospective Studies</subject><subject>Registries</subject><subject>Renal Insufficiency, Chronic - complications</subject><subject>Renal Insufficiency, Chronic - drug therapy</subject><subject>Renal Insufficiency, Chronic - mortality</subject><subject>Statins</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><issn>0002-9149</issn><issn>1879-1913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFUsGO0zAUtBCILYVPAFnishxa_GLHSS4g1C1QsRIruiuOltd5bV2SuNhOpf4U34jTFpD2wsV-Ho1n_N6YkJfApsBAvt1Odbs12tfTjAGfAkwZk4_ICMqimkAF_DEZMcaySQWiuiDPQtimI0Aun5KLTHCRFTIbkV_LqKPt6O0Gvd4daCpvEoBdDPS7jRs623jXWUO_2LrDA72yAXVAetfV6NfOdmt6g970UXfo-kBnLtG1P9BFF9Hvk451Hb1cedfSuEE63-um10fQreiV79d03vRx0FnGo6vuaroIZoNtcp3vj9g3XNsQ_eHNc_JkpZuAL877mNx9nN_OPk-uv35azD5cT4wQZUyrhlxzLkUmZS1MCaWAIhW8kFUOFRN1ea9LxsEIuWKiqkvgCYPSFBWTgo_J5Ul3593PHkNUrQ0Gm-bUpkozFTwRmUzU1w-oW9f7Lr1uYGV5kefJaEzyE8t4F4LHldp526ZBKWBqCFRt1TlQNQSqABQ7qr86q_f3LdZ_b_1JMBHenwiYxrG36FUwKT6DtfVooqqd_a_FuwcKprEpct38wAOGf92okCmmlsOvGj4VcJZlOav4b0DYyX0</recordid><startdate>20140215</startdate><enddate>20140215</enddate><creator>Dasari, Tarun W., MD, MPH</creator><creator>Cohen, David J., MD, MSc</creator><creator>Kleiman, Neal S., MD</creator><creator>Keyes, Michelle J., PhD</creator><creator>Yen, Chen-Hsing, MS</creator><creator>Hanna, Elias B., MD</creator><creator>Saucedo, Jorge F., MD</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7Z</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20140215</creationdate><title>Statin Therapy in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention (from the Evaluation of Drug Eluting Stents and Ischemic Events Registry)</title><author>Dasari, Tarun W., MD, MPH ; Cohen, David J., MD, MSc ; Kleiman, Neal S., MD ; Keyes, Michelle J., PhD ; Yen, Chen-Hsing, MS ; Hanna, Elias B., MD ; Saucedo, Jorge F., MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c448t-c4a15a3364266d4c818417d4c376951904d8ba8031c46f049d8134d818c790643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Cardiovascular</topic><topic>Coronary Artery Disease - complications</topic><topic>Coronary Artery Disease - mortality</topic><topic>Coronary Artery Disease - surgery</topic><topic>Drug Prescriptions - statistics & numerical data</topic><topic>Drug therapy</topic><topic>Drug-Eluting Stents</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Glomerular Filtration Rate</topic><topic>Heart attacks</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Male</topic><topic>Mortality</topic><topic>Percutaneous Coronary Intervention</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Prospective Studies</topic><topic>Registries</topic><topic>Renal Insufficiency, Chronic - complications</topic><topic>Renal Insufficiency, Chronic - drug therapy</topic><topic>Renal Insufficiency, Chronic - mortality</topic><topic>Statins</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dasari, Tarun W., MD, MPH</creatorcontrib><creatorcontrib>Cohen, David J., MD, MSc</creatorcontrib><creatorcontrib>Kleiman, Neal S., MD</creatorcontrib><creatorcontrib>Keyes, Michelle J., PhD</creatorcontrib><creatorcontrib>Yen, Chen-Hsing, MS</creatorcontrib><creatorcontrib>Hanna, Elias B., MD</creatorcontrib><creatorcontrib>Saucedo, Jorge F., MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Physical Education Index</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Biochemistry Abstracts 1</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dasari, Tarun W., MD, MPH</au><au>Cohen, David J., MD, MSc</au><au>Kleiman, Neal S., MD</au><au>Keyes, Michelle J., PhD</au><au>Yen, Chen-Hsing, MS</au><au>Hanna, Elias B., MD</au><au>Saucedo, Jorge F., MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Statin Therapy in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention (from the Evaluation of Drug Eluting Stents and Ischemic Events Registry)</atitle><jtitle>The American journal of cardiology</jtitle><addtitle>Am J Cardiol</addtitle><date>2014-02-15</date><risdate>2014</risdate><volume>113</volume><issue>4</issue><spage>621</spage><epage>625</epage><pages>621-625</pages><issn>0002-9149</issn><eissn>1879-1913</eissn><coden>AJCDAG</coden><abstract>Secondary prevention trials have demonstrated the efficacy of statins in reducing cardiovascular morbidity and mortality in patients with coronary artery disease and events after percutaneous coronary intervention (PCI). However, there are few data describing the clinical value of statins in patients with coronary artery disease and chronic kidney disease (CKD) undergoing PCI. Of 10,148 patients who entered into Evaluation of Drug Eluting Stents and Ischemic Events, a multicenter registry of unselected patients undergoing PCI from July 2004 to December 2007, we studied 2,306 patients with CKD (estimated glomerular filtration rate ≤60 ml/min based on the Modified Diet in Renal Disease calculation). Patients were stratified into those receiving statins at discharge (n = 1,833, 79%) or not (n = 473, 21%). Patients in the statin group had a greater prevalence of hypertension, recent myocardial infarction (MI), and use of β blockers and angiotensin-converting enzyme inhibitors. Outcomes were assessed from discharge through 1-year follow-up. One-year all-cause mortality was 5.7% in statin group versus 8.7% in the no statin group (adjusted hazard ratio 0.55, 95% confidence interval 0.34 to 0.88). The composite of death, MI, and repeat revascularization was lower in statin group (adjusted hazard ratio 0.71, 95% confidence interval 0.51 to 0.99). In conclusion, among patients with CKD undergoing PCI, the prescription of statins at hospital discharge was associated with a significant improvement in subsequent outcomes including mortality and composite end point of death, MI, and repeat revascularization.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>24342762</pmid><doi>10.1016/j.amjcard.2013.11.006</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9149 |
| ispartof | The American journal of cardiology, 2014-02, Vol.113 (4), p.621-625 |
| issn | 0002-9149 1879-1913 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1494306406 |
| source | MEDLINE; Elsevier ScienceDirect Journals; ProQuest Central UK/Ireland |
| subjects | Aged Aged, 80 and over Cardiovascular Coronary Artery Disease - complications Coronary Artery Disease - mortality Coronary Artery Disease - surgery Drug Prescriptions - statistics & numerical data Drug therapy Drug-Eluting Stents Female Follow-Up Studies Glomerular Filtration Rate Heart attacks Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Male Mortality Percutaneous Coronary Intervention Platelet Aggregation Inhibitors - therapeutic use Prospective Studies Registries Renal Insufficiency, Chronic - complications Renal Insufficiency, Chronic - drug therapy Renal Insufficiency, Chronic - mortality Statins Survival Rate Treatment Outcome |
| title | Statin Therapy in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention (from the Evaluation of Drug Eluting Stents and Ischemic Events Registry) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T05%3A26%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Statin%20Therapy%20in%20Patients%20With%20Chronic%20Kidney%20Disease%20Undergoing%20Percutaneous%20Coronary%20Intervention%20(from%20the%20Evaluation%20of%20Drug%20Eluting%20Stents%20and%20Ischemic%20Events%20Registry)&rft.jtitle=The%20American%20journal%20of%20cardiology&rft.au=Dasari,%20Tarun%20W.,%20MD,%20MPH&rft.date=2014-02-15&rft.volume=113&rft.issue=4&rft.spage=621&rft.epage=625&rft.pages=621-625&rft.issn=0002-9149&rft.eissn=1879-1913&rft.coden=AJCDAG&rft_id=info:doi/10.1016/j.amjcard.2013.11.006&rft_dat=%3Cproquest_cross%3E3195386471%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1492575580&rft_id=info:pmid/24342762&rft_els_id=1_s2_0_S0002914913022509&rfr_iscdi=true |